Events Calendar

Presentation in London

24 September 2015
6:00pm at the Chesterfield Mayfair Hotel

(click here to register):
Proactive Investors' One2One Forum

 

 

Past Events

Annual General Meeting

7 August 2015

Notice of Annual General Meeting
18.6k PDF


 

Annual General Meeting

7 August 2014

Notice of Annual General Meeting
17.1k PDF

Extraordinary General Meeting

7 August 2014

Circular and Notice of Extraordinary General Meeting
17.9k PDF


 

Annual General Meeting

13 August 2013

Notice of Annual General Meeting
16.4k PDF


 

Annual General Meeting

26 July 2012



Annual General Meeting

1 September, 2011


Preliminary Results

23 June, 2011

Release of Amphion’s Preliminary Results for the year ended 30 December 2010


Amphion Partner Company Showcase

8 June 2010

Featuring:
Mr. Richard C.E. Morgan, CEO, Amphion Innovations plc
Mr. Zaki Hosny, CEO, Motif BioSciences, Inc.
Mr. Jerel Whittingham, Executive Chairman, Myconostica Ltd.


Annual General Meeting

8 June 2010


Amphion Partner Company Showcase

4 June 2009

Featuring:
Mr. Richard Morgan, CEO, Amphion Innovations plc
Mr. Chris Sanders, CEO, PrivateMarkets, Inc.
Dr. Roddy Carter, President and CEO, WellGen, Inc.

Click here for presentation 3.02m PDF


Annual General Meeting

4 June 2009


Preliminary Results

March 16, 2009
Release of Amphion’s Preliminary Results for the year ended 31 December 2008.


Launch of the Kromek Liquid Explosive Scanners

Friday, 5 December 2008
The British Embassy, Washington, DC


Amphion Innovations plc 3rd New York Business Symposium

Commercializing IP: A Road Map for Successful Investment

Thursday, 30 October, 2008

Click here for presentation - 7.72m PDF

Featured Speakers
Mr. Richard Morgan, CEO Amphion Innovations plc - Opening Remarks
Dr. Arnab Basu, CEO Kromek
Mr. Chris Sanders, CEO PrivateMarkets Inc

Agenda
4:00 pm Registration
4:30 pm Program Start
6:30 pm Adjourn / Cocktail Reception

For more informations please contact
Sandra Haughton
shaughton@amphionplc.com
Tel: 212 210 6205


12 June 2008

Annual General Meeting


12 June 2008

Amphion's 3rd London Business Symposium
Commercialising University Intellectual Property

"Risk comes from not knowing what you're doing." - Warren Buffett

High growth companies based on University-generated intellectual property can offer exciting opportunities for wealth creation. They are also famously challenging.

With over 20 years' experience and multiple success stories, Amphion's proven company building approach is now being successfully applied in the UK.

This symposium should help generate insights into how Amphion is applying its unique model to two exciting spin-out companies.

Featured Speakers
Mr. Richard Morgan, CEO Amphion Innovations plc
Dr. Arnab Basu, CEO Kromek, Ltd. (formerly DSC, Ltd.)
Dr. David Denning, Chairman Myconostica, Ltd.

Please click here to view the full presentation - 3.57m PDF

For more information regarding this event, please contact
shaughton@amphionplc.com


March 13.2008
Amphion Innovations plc
Preliminary Results for the year to 31 December 2007
  225k PDF


December 5th, 2007
Amphion held its second New York based Science and Business Symposium titled, “Investing in Patented Security Technology”.

Speakers
Mr. Bob Bramson, Intellectual Property Industry Expert - Licensing and Enforcement of Intellectual Property
Dr. Arnab Basu, CEO DSC - X-Ray Detection for Security & Medicine
Mr. Allan Griebenow, CEO AXCESS - RFID Systems for Security and Identification

Please click here to view the full presentation   2.79m PDF


Please click here to view Amphion’s White Paper:
Paupers, Patents, and Princes: Leveraging Intellectual Property When Building Companies”  590k PDF

 

Please direct enquiries to:
Charlie Morgan
Amphion Innovations
330 Madison Avenue
New York, NY 10017
cmorgan@amphionplc.com
(212) 210 6224


Legal Notice
Unless otherwise stated information on this Website is based on management information and estimates. The information and opinions contained on this Website are provided as at the date of the last publication of the Website and are subject to change without notice. Some statements may be forward-looking statements. Actual results may differ from those expressed in such statements, depending on a variety of factors. Past performance of the Company or the Ordinary Shares cannot be relied on as a guide to future performance. Any forward-looking information contained on this Website has been prepared on the basis of a number of assumptions which may prove to be incorrect, and accordingly, actual results may vary.
Law may restrict the distribution of the information on this Website in certain jurisdictions and therefore persons into whose possession this information comes should inform themselves about and observe any such restrictions. Any such distribution could result in a violation of the law of such jurisdiction. Accordingly, this information should not be distributed, published or reproduced in whole or in part or disclosed by recipients and in particular should not be distributed to persons with addresses in the United States of America, Canada, Japan, Australia, New Zealand, or The Republic of Ireland or to any corporation, partnership, or other entity created or organized under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement.
This Website and the information contained herein do not constitute an offer or a solicitation of an offer for the sale or purchase of any securities. The information provided on this website is for informational purposes only and does not constitute investment advice. The information contained in this website may include "forward-looking statements". These forward-looking statements are often preceded by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "intend," "assume," "will" and similar expressions. Amphion Innovations plc cautions investors not to place undue reliance on the forward-looking statements included in this Website. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to be far different from those suggested by the forward-looking statements. The Ordinary Shares of the Company have not been, and will not be registered under the United States Securities Act of 1933, as amended ("the Securities Act") and, subject to certain exceptions, may not be offered, subscribed or sold within the United States, or for the account or benefit of, or to, US persons (as defined in Regulation S under the Securities Act ("Regulation S"). The Ordinary Shares are not being offered, subscribed and sold nor are solicitations offers to buy the Ordinary Shares being made within the United States or to U.S. persons. The Ordinary Shares of the Company are not being offered, subscribed and sold nor are solicitations of an offer to buy or subscribe for Ordinary Shares in any jurisdiction in which such offer, invitation or solicitation is unlawful. The Ordinary Shares have not been and will not be registered under the securities legislation of any country, territory or jurisdiction where to do so may contravene local securities law and regulations.

Top of page